In MASLD, decreased levels of circulating α-ketoglutarate (AKG), reduced expression of orosomucoid 2 (ORM2), and fibroblast growth factor 4 (FGF4) are closely associated with impaired AMPK activity (29–31). Here, PRKAB1 is linked to metabolic dysfunction-associated steatotic liver disease.